Global leading candidate in Phase 2b for the treatment of adenoviral conjunctivitis.
With acute conjunctivitis representing 1% of all primary care visits in the US, we see a significant need and opportunity.
© 2021 Okogen, Inc. All Rights Reserved
Okogen, Inc.332 Encinitas Blvd. Suite 102Encinitas, CA 92024, USA
Okogen Pty Ltd Level 9, 31 Queen St Melbourne, VIC 3000 AUS